AI-Driven Firefly Neurosciences Has Discovered Breakthrough Cognitive Brain Age Biomarker For Alzheimer’s Detection

Yesterday, shares of the AI-driven company focused on improving brain health outcomes Firefly Neuroscience, Inc. (Nasdaq: AIFF), surged over 100% after announcing advancements in its FDA-cleared BNA™ technology platform for assessing “brain age,” the biological age of a person’s brain. The system utilizes Resting EEG and Cognitive EEG (ERP) data, marking the first successful use of ERP-measured cognitive data to evaluate brain age.

This innovation could reveal significant disparities between brain and chronological age, serving as a potential risk factor for conditions like dementia. The ability to measure brain age with EEG offers a scalable and proactive tool for early screening and monitoring of Alzheimer’s disease.

Executive Chairman Greg Lipschitz emphasized the breakthrough’s significance in advancing brain health and commended the team’s dedication to impactful innovation in a statement, “This breakthrough underscores our commitment to pushing the boundaries of innovation in brain health, ultimately with the aim of making a meaningful impact on patients’ lives. I’m incredibly proud of our team for their dedication and ingenuity in bringing this vision to fruition.”